Warning: The NCBI web site requires JavaScript to function. more...
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Lourida ES, Georgiadis AN, Papavasiliou EC, Papathanasiou AI, Drosos AA, Tselepis AD.
Arthritis Res Ther. 2007;9(1):R19.
Related citations
The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD.
Prostaglandins Leukot Essent Fatty Acids. 2006 Aug;75(2):117-26. Epub 2006 Jul 14.
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD.
Atherosclerosis. 2008 Jan;196(1):289-97. Epub 2006 Nov 30.
Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia.
Tsouli SG, Kiortsis DN, Lourida ES, Xydis V, Tsironis LD, Argyropoulou MI, Elisaf M, Tselepis AD.
J Lipid Res. 2006 Oct;47(10):2208-14. Epub 2006 Aug 3.
Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia.
Tsouli SG, Kiortsis DN, Xydis V, Argyropoulou MI, Elisaf M, Tselepis AD.
Angiology. 2006 Oct-Nov;57(5):615-22.
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Tellis CC, Tselepis AD.
Biochim Biophys Acta. 2009 May;1791(5):327-38. Review.
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD.
Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2236-43. Epub 2007 Jul 26.
Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
Cvetkovic JT, Wållberg-Jonsson S, Ahmed E, Rantapää-Dahlqvist S, Lefvert AK.
Rheumatology (Oxford). 2002 Sep;41(9):988-95.
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL.
J Am Coll Cardiol. 2003 Feb 5;41(3):360-70.
Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes.
Yang M, Chu EM, Caslake MJ, Edelstein C, Scanu AM, Hill JS.
Biochim Biophys Acta. 2010 Feb;1801(2):176-82. Epub 2009 Nov 4.
Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Wootton PT, Stephens JW, Hurel SJ, Durand H, Cooper J, Ninio E, Humphries SE, Talmud PJ.
Atherosclerosis. 2006 Nov;189(1):149-56. Epub 2006 Jan 24.
Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis.
Wada Y, Kuroda T, Murasawa A, Tanabe N, Nakano M, Gejyo F.
Clin Exp Rheumatol. 2005 Jul-Aug;23(4):482-6.
Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.
Vickers KC, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R, Holvoet P, Morrisett JD.
J Lipid Res. 2009 Sep;50(9):1735-43. Epub 2009 Apr 9.
Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis.
Peters MJ, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, Dijkmans BA, Voskuyl AE.
J Rheumatol. 2008 Aug;35(8):1495-9. Epub 2008 Jun 15.
Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, Witztum JL, Xu Q.
J Am Coll Cardiol. 2006 Jun 20;47(12):2436-43. Epub 2006 May 30.
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH.
Circulation. 2004 Jun 29;109(25):3164-70. Epub 2004 Jun 7.
The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
Orem A, Yandi YE, Vanizor B, Cimşit G, Uydu HA, Malkoç M.
Clin Biochem. 2002 May;35(3):217-24.
Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease.
Faviou E, Vourli G, Nounopoulos C, Zachari A, Dionyssiou-Asteriou A.
Free Radic Res. 2005 Apr;39(4):419-29.
High plasma immunoglobulin (Ig) A and low IgG antibody titers to oxidized low-density lipoprotein are associated with markers of glucose metabolism.
Sämpi M, Veneskoski M, Ukkola O, Kesäniemi YA, Hörkkö S.
J Clin Endocrinol Metab. 2010 May;95(5):2467-75. Epub 2010 Mar 23.
High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM, Bombig MT, Carvalho AC, Monteiro AM, Ramos E, Gidlund M, Figueiredo Neto AM, Izar MC.
Clin Chim Acta. 2009 Aug;406(1-2):113-8. Epub 2009 Jun 10.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on